Share on LinkedInShare on LinkedIn

ARTICLE · 22 NOVEMBER 2012

Intellectual Property Weekly Abstracts Bulletin (Week Of November 19, 2012)

Borden Ladner Gervais LLP
Borden Ladner Gervais LLP
Contributor
Borden Ladner Gervais LLP

Borden Ladner Gervais LLP

With over 750 lawyers, intellectual property agents and other professionals, BLG services...

View firm profile
Explore more from Borden Ladner Gervais LLP

Pfizer has filed a motion to amend the recent judgment of the Supreme Court of Canada (SCC) regarding sildenafil. In the alternative, Pfizer is seeking a rehearing on the issue of remedy.

CanadaIntellectual Property

NOC Proceedings

Motion to Amend Judgment in SCC Decision Relating to Sildenafil Filed
Teva Canada Ltd. v. Pfizer Canada Inc.
Drug: VIAGRA®.

Pfizer has filed a motion to amend the recent judgment of the Supreme Court of Canada (SCC) regarding sildenafil. In the alternative, Pfizer is seeking a rehearing on the issue of remedy. The motion argues that the SCC granted a remedy that exceeds its jurisdiction by holding that Pfizer's patent is invalid. The proceeding in the Federal Court was an application brought pursuant to the Patented Medicines (Notice of Compliance) Regulations, and thus Pfizer argues that the SCC could only dismiss the application, and not invalidate the patent at issue. The SCC's decision is found here, and our summary is here.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from